Featured Products & Services

31. Connected Solutions For Self-Injection 8/20/2026

    From enabling connected clinical trials to supporting digital therapy management, our solutions help improve clinical trial operational efficiency and data quality, strengthen commercial success, and empower patients to self-manage their therapy.

32. Nasal Dosage Form Development 10/23/2024

    Upperton have developed UpperNose™, a nasal product development approach designed to streamline the development process for nasal dosage forms.

33. Bionanoparticle Technology 4/24/2023

    Nanoform’s proprietary bionanoparticle technology can deliver large-molecule drug particles as small as 50 nm while retaining biological activity. This can not only enable more patient-friendly approaches to drug delivery, but also potentially higher loads of active ingredients.

34. Sterile Formulation Development 7/1/2022

    With over 20 years of experience, PCI’s strength lies in our ability to manage products with unique challenges ranging from small molecules presenting with solubility issues or a labile molecule that is only stable as a liquid presentation for a short time.

35. Isolator Barrier Pharmaceutical Aseptic Filling Systems 11/12/2020

    ASEPTiCell is integrated with isolator-barrier technologies to fully enclose and tightly control the aseptic environment for ideal conditions for processing sterile drug products. The system can be configured with a Restricted Access Barrier System (RABS) or an aseptic isolator to provide uninterrupted aseptic conditions during production. With isolator integrated systems, the ASEPTiCell is completely compatible with repeated in-situ bio-decontamination using hydrogen peroxide to further enhance the sterility assurance of the system.

36. cGMP Aseptic Manufacturing And Sterile Fill-Finish 1/28/2022

    Experienced CDMOs will implement a cGMP aseptic manufacturing and sterile fill-finish policy to improve drug bioavailability. Aseptic fill-finish is a process in which the drug product, container, and container closure are sterilized separately and then integrated. Combining the drug, container, and closure in a clean room using special equipment that is self-contained in a sterile environment meets FDA guidelines related to cGMP.

37. Injection Molding 8/24/2020

    Capabilities that improve efficiency and accelerate development.

    B. Braun's OEM Division offers a variety of in-house molding capabilities including injection molding, insert molding and over molding. They own a primary 400,000-square-foot U.S. plant that includes a 16,500-square-foot ISO Class 8 molding facility housing some of B. Braun’s 80 injection molding presses, which range from 55-330 tons.